| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
|
Dieci, M.V.
|
|
|
30 |
3 |
p. 418-423
|
article
|
| 2 |
Biological background of the genomic variations of cf-DNA in healthy individuals
|
Liu, J.
|
|
|
30 |
3 |
p. 464-470
|
article
|
| 3 |
Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses
|
Abbosh, C.
|
|
|
30 |
3 |
p. 358-359
|
article
|
| 4 |
Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment
|
Poortmans, P.M.P.
|
|
|
30 |
3 |
p. 348-350
|
article
|
| 5 |
Corrections to “Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy”
|
McCoach, C.E.
|
|
|
30 |
3 |
p. 492
|
article
|
| 6 |
Corrections to “Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium”
|
Quaglino, P.
|
|
|
30 |
3 |
p. 494
|
article
|
| 7 |
Corrections to “Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study”
|
Molassiotis, A.
|
|
|
30 |
3 |
p. 493
|
article
|
| 8 |
Corrections to “Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer”
|
Overman, M.J.
|
|
|
30 |
3 |
p. 495
|
article
|
| 9 |
Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer
|
Dong, D.
|
|
|
30 |
3 |
p. 431-438
|
article
|
| 10 |
Editorial board
|
|
|
|
30 |
3 |
p. ii-iii
|
article
|
| 11 |
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
|
Sundar, R.
|
|
|
30 |
3 |
p. 424-430
|
article
|
| 12 |
Evolutionary dynamics of residual disease in human glioblastoma
|
Spiteri, I.
|
|
|
30 |
3 |
p. 456-463
|
article
|
| 13 |
Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way
|
Telli, M.L.
|
|
|
30 |
3 |
p. 347-348
|
article
|
| 14 |
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
|
Condorelli, R.
|
|
|
30 |
3 |
p. 365-373
|
article
|
| 15 |
HER2: defining a Neu target in non-small-cell lung cancer
|
Ekman, S.
|
|
|
30 |
3 |
p. 353-355
|
article
|
| 16 |
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
|
Wang, Y.
|
|
|
30 |
3 |
p. 447-455
|
article
|
| 17 |
Making adjuvant therapy decisions with uncertain data
|
Gyawali, B.
|
|
|
30 |
3 |
p. 361-364
|
article
|
| 18 |
Making immunotherapy ‘cold’ tumours ‘hot’ by chemotherapy-induced mutations—a misconception
|
Helleday, T.
|
|
|
30 |
3 |
p. 360-361
|
article
|
| 19 |
Novel patterns of response under immunotherapy
|
Borcoman, E.
|
|
|
30 |
3 |
p. 385-396
|
article
|
| 20 |
Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group
|
Bröckelmann, P.J.
|
|
|
30 |
3 |
p. 490-491
|
article
|
| 21 |
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
|
Adams, S.
|
|
|
30 |
3 |
p. 397-404
|
article
|
| 22 |
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
|
Adams, S.
|
|
|
30 |
3 |
p. 405-411
|
article
|
| 23 |
Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer
|
Evron, E.
|
|
|
30 |
3 |
p. 412-417
|
article
|
| 24 |
Recent advances in circulating nucleic acids in oncology
|
Otandault, A.
|
|
|
30 |
3 |
p. 374-384
|
article
|
| 25 |
Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma
|
Shepherd, S.T.C.
|
|
|
30 |
3 |
p. 355-357
|
article
|
| 26 |
Table of Contents
|
|
|
|
30 |
3 |
p. iv-vi
|
article
|
| 27 |
The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target
|
Takimoto, C.H.
|
|
|
30 |
3 |
p. 486-489
|
article
|
| 28 |
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
|
Vidal, J.
|
|
|
30 |
3 |
p. 439-446
|
article
|
| 29 |
Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer
|
Gambardella, V.
|
|
|
30 |
3 |
p. 351-352
|
article
|
| 30 |
Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3)
|
Zuo, H.
|
|
|
30 |
3 |
p. 478-485
|
article
|
| 31 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
|
Haddad, R.I.
|
|
|
30 |
3 |
p. 471-477
|
article
|
Journal description